Psoriatic Arthritis | Disease Landscape & Forecast | G7 | 2022

The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—Janssen’s Tremfya and AbbVie’s Rinvoq and Skyrizi. Furthermore, a series of approvals expected in the next decade will likely present an increasing challenge to the dominance of the TNF inhibitors, especially as biosimilars are increasingly accepted as alternatives to more-expensive branded therapies and drugs with novel mechanisms of action become available. Interleukin (IL)-17 and IL-23 inhibitors, in particular, are poised to capture substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the positions of current market leaders. The impending entry of the first TYK2 inhibitor (BMS’s deucravacitinib), an additional IL-17 inhibitor (UCB’s bimekizumab), and an IL-23 inhibitor (Sun Pharma’s tildrakizumab) will also create interesting market dynamics.

Questions answered

  • What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in different markets react to these less expensive therapies?
  • How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What is the physician perception of these therapies?
  • What emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? What novel mechanisms of action are considered good clinical targets for this disease?
  • What unmet needs remain in the treatment of PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?

Content highlights:

Geographies: United States, EU5, Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2031, segmented by brands / generics.

Emerging therapies: Phase III/PR: 3 drugs; Phase II: 3 drugs.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report